CJC-1295 + GHRP-2

Source-reported examples · not treatment recommendations

Amount

100–300 micrograms total blend per day in the narrative

Frequency

Once daily in the narrative

Cycle / observation period

8–12 weeks; source also mentions 16 weeks

Route / research model

Subcutaneous

The source itself says its cited acute intravenous study does not define the bedtime subcutaneous blend schedule. The narrative is not a verified trial protocol.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.

• Original human experiments have examined GHRH with GHRP-2. Their results depend on the protocol and population, and they do not establish the performance of an unspecified CJC-1295 product. ^{[1] [2]}
• A 1995 study examined GH responses to GHRH(1-29) and GHRP-2 separately and together in eight healthy, non-obese men. The investigators did not demonstrate synergy in that experiment. ^[1]
• A 2004 study in healthy older adults investigated GHRP-2 and GHRH under several acute and longer exposure conditions. Its abstract reports that combined stimulation over 24 hours was more effective at driving GH secretion than either agonist alone. It also reports sex-related differences in acute synergy. ^[2]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. 1995 experiment
2. 2004 study
3. J Clin Endocrinol Metab (2006)Further reading · Listed in reference bibliography.
4. J Clin Endocrinol Metab (1998)Further reading · Listed in reference bibliography.
5. J Clin Endocrinol Metab (1998)Further reading · Listed in reference bibliography.
6. J Clin Endocrinol Metab (2005)Further reading · Listed in reference bibliography.
7. Peptides (1997)Further reading · Listed in reference bibliography.
8. Bowers et al., Journal of Clinical Endocrinology and Metabolism (1990)Further reading · Listed in reference bibliography.
9. CDCGeneral guidance · Listed in reference bibliography.
10. CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
11. U.S. Food and Drug AdministrationRegulatory / product information · Listed in reference bibliography.
12. NCBI BookshelfFurther reading · Listed in reference bibliography.
13. Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.